Northland Securities Predicts MiMedx Group Q1 Earnings

MiMedx Group, Inc (NASDAQ:MDXG) – Equities researchers at Northland Securities cut their Q1 2026 earnings estimates for MiMedx Group in a report released on Wednesday, February 4th. Northland Securities analyst C. Byrnes now expects that the company will post earnings per share of $0.00 for the quarter, down from their previous forecast of $0.02. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Securities also issued estimates for MiMedx Group’s Q3 2026 earnings at $0.04 EPS and Q4 2026 earnings at $0.05 EPS.

Other research analysts have also issued reports about the company. Lake Street Capital reduced their target price on MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 20th. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Mizuho cut their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, December 17th. Finally, Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.67.

MiMedx Group Stock Performance

Shares of MDXG stock opened at $5.03 on Friday. MiMedx Group has a 12-month low of $4.89 and a 12-month high of $8.65. The business’s fifty day simple moving average is $6.28 and its 200-day simple moving average is $6.77. The company has a current ratio of 4.41, a quick ratio of 3.95 and a debt-to-equity ratio of 0.07. The company has a market cap of $744.95 million, a PE ratio of 18.63 and a beta of 1.59.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. CWM LLC boosted its position in MiMedx Group by 63.8% in the second quarter. CWM LLC now owns 4,857 shares of the company’s stock valued at $30,000 after buying an additional 1,892 shares during the last quarter. Legato Capital Management LLC lifted its stake in MiMedx Group by 18.5% during the 3rd quarter. Legato Capital Management LLC now owns 17,341 shares of the company’s stock valued at $121,000 after acquiring an additional 2,708 shares during the period. HighMark Wealth Management LLC lifted its stake in MiMedx Group by 5.4% during the 3rd quarter. HighMark Wealth Management LLC now owns 55,878 shares of the company’s stock valued at $390,000 after acquiring an additional 2,878 shares during the period. SkyView Investment Advisors LLC boosted its holdings in shares of MiMedx Group by 3.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock valued at $523,000 after acquiring an additional 3,032 shares during the last quarter. Finally, Rafferty Asset Management LLC increased its stake in shares of MiMedx Group by 5.2% in the third quarter. Rafferty Asset Management LLC now owns 66,240 shares of the company’s stock worth $462,000 after acquiring an additional 3,262 shares during the period. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.